40
nanotimes
Companies Facts
are being applied to accelerating and completing both VivaGel®
Bacterial Vaginosis Phase 3 pro-
grams (Treatment, and Prevention of Recurrence) supporting an NDA filing and commercial licence, as well as advancing the Company’s drug delivery and agrochemical programs.
Furthermore, Starpharma Holdings (ASX: SPL, OTCQX: SPHRY) released animal data which de- monstrated that its dendrimer-docetaxel formula- tion applying Starpharma’s dendrimer technolo- gy to the leading chemotherapy drug docetaxel was significantly more efficacious than docetaxel (Taxotere®
a leading chemotherapy drug used to treat a wide range of solid tumours including breast, lung and prostate. It is marketed by Sanofi Aventis as Taxo- tere®
12-01 :: January 2012
cost-efficient hydrogenation with superior yield when compared to conventional methods.
) in a breast cancer model. Docetaxel is and generated sales in excess of US$3 billion
in 2010. Starpharma conducted the latest study, a breast cancer xenograft in mice, as part of its drug delivery program for docetaxel - having already demonstrated a marked improvement in the water solubility of docetaxel with its dendrimer formulati- on. This study was designed to assess the efficacy of Starpharma’s dendrimer-docetaxel formulations in treating cancer.
http://www.starpharma.com H -Cube® by ThalesNano is a continuous-flow hydrogenation reactor. A revolutionary bench-
top standalone hydrogenation reactor, uniquely combining continuous-flow microchemistry with endogenous on-demand hydrogen generation and a disposable catalyst cartridge system. It allows fast and
T
http://www.youtube.com/watch?v=bdbLVQqaKd4
egal Corporation (NASDAQ: TGAL) has awarded patents to multiple bidders for three of the four
bid lots of Tegal’s NLD Patent Portfolio recently offered for sale for an aggregate consideration of approximately $4M. To date, approximately $3.6M has been received. Tegal sold over 30 patents from the NLD portfolio – which includes more than 35 U.S. and international patents in the areas of pulsed- chemical vapor deposition (CVD), plasma-enhanced atomic-layer deposition (ALD) and NLD.
In March 2010, Tegal sold its legacy thin-film etch and physical vapor deposition (PVD) product lines to OEM Group, Inc. of Gilbert AZ, and in February of this year, sold its deep reactive ion etch (DRIE) assets to SPTS of Newport, Wales, UK.
http://www.tegal.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97